
Please try another search
Lirum Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focusing on the treatment of debilitating diseases. Its product LX-101, an insulin-like growth factor-1 receptor-directed agent, treats patients with various cancers and autoimmune diseases, including thyroid eye disease. The company was incorporated in 2021 and is based in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Kenneth J. Zuerblis | 66 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review